Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
- Indications Ragweed pollen hypersensitivity; Rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 27 Feb 2023 Results assessing the Onset of clinicaleffect was evaluated for grass, ragweed, tree, and house dust mite (HDM)sublingual immunotherapy (SLIT)-tablets from NCT00227279, NCT00783198 and EudraCT2015-004821-15 studies, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 01 Jun 2013 Results published in the Annals of Allergy, Asthma and Immunology.
- 08 May 2013 License application for ragweed allergy immunotherapy tablet was accepted for review by the US FDA, according to an ALK-Abello media release.